Last 12 months
Inside the activity.
10 purchase rows · 7 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 4 |
| Dec 2025 | 0 | 1 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 2 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 4 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 1 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 01, 2020 Filed Jan 3, 2020 21:18 UTC |
Ballinger Kevin J.EVP & Pres, Interven Cardio
|
Exercise / conversionCommon Stock | 16,117 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-000289 · doc4.xml · nonDerivative · entry 1 Ballinger Kevin J. · CIK 0001566080 · EVP & Pres, Interven Cardio 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 96,174 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · shares: On February 28, 2017, the reporting person was awarded a target number of performance share units under the Company's 2017 Free Cash Flow Performance Share Program, the actual number of which to be earned by the reporting person based on the Company's 2017 adjusted free cash flow measured against its 2017 financial plan over the one-year performance period ending December 31, 2017 and subject to the completion of a three-year individual service period (inclusive of the performance period). On February 12, 2018, the number of the target performance share units as to which the performance criteria had been satisfied was determined. The Performance Share Units so determined vested in whole upon the completion of the individual service period that ended on December 31, 2019. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 107,692 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-015842 · doc4.xml · derivative · entry 5 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 107,692 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the grant. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
SaleCommon Stock | 107,692 | $45.00 | $4,846,140.00 |
DisclosureSEC source: 0001225208-19-015842 · doc4.xml · nonDerivative · entry 3 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,685 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC |
Fitzgerald Joseph MichaelEVP & President, Rhythm Mgmt
|
Exercise / conversionCommon Stock | 107,692 | $7.41 | $797,997.72 |
DisclosureSEC source: 0001225208-19-015842 · doc4.xml · nonDerivative · entry 2 Fitzgerald Joseph Michael · CIK 0001484186 · EVP & President, Rhythm Mgmt 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,377 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 24,220 | $0.00 Strike: $7.39 | $0.00 |
DisclosureSEC source: 0001225208-19-015841 · doc4.xml · derivative · entry 4 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 24,220 shares Expires 2023-02-28 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · date: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 28, 2014, the first anniversary of the date of grant. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC |
Carruthers WendySVP, Human Resources
|
SaleCommon Stock | 24,220 | $45.03 | $1,090,670.20 |
DisclosureSEC source: 0001225208-19-015841 · doc4.xml · nonDerivative · entry 3 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,848 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $45.00 to $45.08, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2019 Filed Dec 16, 2019 21:08 UTC |
Carruthers WendySVP, Human Resources
|
Exercise / conversionCommon Stock | 24,220 | $7.39 | $178,985.80 |
DisclosureSEC source: 0001225208-19-015841 · doc4.xml · nonDerivative · entry 2 Carruthers Wendy · CIK 0001563565 · SVP, Human Resources 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,068 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 05, 2019 Filed Feb 14, 2020 21:13 UTC |
Sununu John EDirector
|
GiftCommon Stock | 6,100 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-20-002370 · doc5.xml · nonDerivative · entry 1 Sununu John E · CIK 0001458974 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,155 Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 21:21 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,623 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-19-015300 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,007 Underlying: Common Stock · 9,623 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 21:21 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 9,623 | $42.89 | $412,712.19 |
DisclosureSEC source: 0001225208-19-015300 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.74 to $43.01, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 04, 2019 Filed Dec 5, 2019 21:21 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 9,623 | $13.08 | $125,868.84 |
DisclosureSEC source: 0001225208-19-015300 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:21 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionDeferred Stock Units · Derivative | 649 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015299 · doc4.xml · derivative · entry 5 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,596 Underlying: Common Stock · 649 shares Expires 2023-12-03 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 3, 2019, the first anniversary of the date of grant. Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:21 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Tax withholdingCommon Stock | 199 | $42.61 | $8,479.39 |
DisclosureSEC source: 0001225208-19-015299 · doc4.xml · nonDerivative · entry 3 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,736 Read SEC document |
| December 03, 2019 Filed Dec 5, 2019 21:21 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
Exercise / conversionCommon Stock | 649 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015299 · doc4.xml · nonDerivative · entry 2 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,935 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:15 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-19-015213 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,997 Underlying: Common Stock · 5,000 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:15 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $43.33 | $216,650.00 |
DisclosureSEC source: 0001225208-19-015213 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 02, 2019 Filed Dec 3, 2019 21:15 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $6.28 | $31,400.00 |
DisclosureSEC source: 0001225208-19-015213 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionDeferred Stock Units · Derivative | 2,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015216 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,328 shares Expires 2019-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Tax withholdingCommon Stock | 1,241 | $43.25 | $53,673.25 |
DisclosureSEC source: 0001225208-19-015216 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,443.99 Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:16 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 2,328 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015216 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 78,684.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:17 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Exercise / conversionDeferred Stock Units · Derivative | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015217 · doc4.xml · derivative · entry 3 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,417 Underlying: Common Stock · 11,472 shares Expires 2022-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2018, the first anniversary of the date of grant. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:17 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Tax withholdingCommon Stock | 3,373 | $43.25 | $145,882.25 |
DisclosureSEC source: 0001225208-19-015217 · doc4.xml · nonDerivative · entry 2 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,487 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:17 UTC |
Ralls-Morrison DesireeSVP, GC and Corp Secretary
|
Exercise / conversionCommon Stock | 11,472 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015217 · doc4.xml · nonDerivative · entry 1 Ralls-Morrison Desiree · CIK 0001723937 · SVP, GC and Corp Secretary 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,860 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:16 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionDeferred Stock Units · Derivative | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015215 · doc4.xml · derivative · entry 3 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,025 Underlying: Common Stock · 2,025 shares Expires 2020-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F3 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant. F3 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2016, the first anniversary of the date of grant. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:16 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Tax withholdingCommon Stock | 475 | $43.25 | $20,543.75 |
DisclosureSEC source: 0001225208-19-015215 · doc4.xml · nonDerivative · entry 2 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,019 F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:16 UTC |
Wang Xin WarrenSVP and Pres, Asia Pacific
|
Exercise / conversionCommon Stock | 2,025 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015215 · doc4.xml · nonDerivative · entry 1 Wang Xin Warren · CIK 0001725283 · SVP and Pres, Asia Pacific 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 77,494 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:15 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Exercise / conversionDeferred Stock Units · Derivative | 2,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015214 · doc4.xml · derivative · entry 3 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 2,910 shares Expires 2019-12-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. F2 · derivative.exercise_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. F2 · derivative.expiration_date: Shares of common stock will be issued to the reporting person in five equal annual installments beginning on December 1, 2015, the first anniversary of the date of grant. Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:15 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Tax withholdingCommon Stock | 856 | $43.25 | $37,022.00 |
DisclosureSEC source: 0001225208-19-015214 · doc4.xml · nonDerivative · entry 2 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,653 Read SEC document |
| December 01, 2019 Filed Dec 3, 2019 21:15 UTC |
Monson JonathanVP, Corp Controller and CAO
|
Exercise / conversionCommon Stock | 2,910 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015214 · doc4.xml · nonDerivative · entry 1 Monson Jonathan · CIK 0001779170 · VP, Corp Controller and CAO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,509 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each deferred stock unit represents the Company's commitment to issue one share of Boston Scientific common stock. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:08 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,552 | $0.00 Strike: $17.26 | $0.00 |
DisclosureSEC source: 0001225208-19-015054 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,851 Underlying: Common Stock · 20,552 shares Expires 2026-02-22 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 22, 2017, the first anniversary of the date of grant. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:08 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 20,552 | $43.27 | $889,322.03 |
DisclosureSEC source: 0001225208-19-015054 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $43.27 to $43.28, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 27, 2019 Filed Dec 2, 2019 21:08 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 20,552 | $17.26 | $354,727.52 |
DisclosureSEC source: 0001225208-19-015054 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 275,746 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:08 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,866 | $0.00 Strike: $7.74 | $0.00 |
DisclosureSEC source: 0001225208-19-015011 · doc4.xml · derivative · entry 3 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 9,866 shares Expires 2020-02-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 26, 2011, the first anniversary of the date of grant. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:08 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
SaleCommon Stock | 22,487 | $42.70 | $960,255.61 |
DisclosureSEC source: 0001225208-19-015011 · doc4.xml · nonDerivative · entry 2 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 76,356.99 F1 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $42.66 to $42.73, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 26, 2019 Filed Nov 27, 2019 21:08 UTC |
Thepaut Eric Francis YvesSVP & Pres, Eur, Mid-East, Afr
|
Exercise / conversionCommon Stock | 9,866 | $7.74 | $76,362.84 |
DisclosureSEC source: 0001225208-19-015011 · doc4.xml · nonDerivative · entry 1 Thepaut Eric Francis Yves · CIK 0001631992 · SVP & Pres, Eur, Mid-East, Afr 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,843.99 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| November 20, 2019 Filed Nov 21, 2019 21:10 UTC |
Sorenson John BradleySVP, Manuf & Sup Chn
|
SaleCommon Stock | 4,800 | $42.58 | $204,392.64 |
DisclosureSEC source: 0001225208-19-014738 · doc4.xml · nonDerivative · entry 1 Sorenson John Bradley · CIK 0001629277 · SVP, Manuf & Sup Chn 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,585 Read SEC document |
| November 08, 2019 Filed Nov 12, 2019 21:04 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
SaleCommon Stock | 1,104 | $40.75 | $44,990.76 |
DisclosureSEC source: 0001225208-19-014374 · doc4.xml · nonDerivative · entry 2 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,815 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:30 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,623 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-19-014138 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,630 Underlying: Common Stock · 9,623 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:30 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 9,623 | $41.66 | $400,894.18 |
DisclosureSEC source: 0001225208-19-014138 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 04, 2019 Filed Nov 5, 2019 21:30 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 9,623 | $13.08 | $125,868.84 |
DisclosureSEC source: 0001225208-19-014138 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:26 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $6.28 | $0.00 |
DisclosureSEC source: 0001225208-19-014049 · doc4.xml · derivative · entry 3 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,997 Underlying: Common Stock · 5,000 shares Expires 2022-02-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 27, 2013, the first anniversary of the date of grant. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:26 UTC |
Pierce David AEVP,Pres MedSurg
|
SaleCommon Stock | 5,000 | $42.05 | $210,250.00 |
DisclosureSEC source: 0001225208-19-014049 · doc4.xml · nonDerivative · entry 2 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 24,201 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| November 01, 2019 Filed Nov 4, 2019 21:26 UTC |
Pierce David AEVP,Pres MedSurg
|
Exercise / conversionCommon Stock | 5,000 | $6.28 | $31,400.00 |
DisclosureSEC source: 0001225208-19-014049 · doc4.xml · nonDerivative · entry 1 Pierce David A · CIK 0001529751 · EVP,Pres MedSurg 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,201 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. Read SEC document |
| October 31, 2019 Filed Dec 5, 2019 21:21 UTC |
Mirviss Jeffrey B.SVP&Pres, Periph Intervent
|
GiftCommon Stock | 230 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-015299 · doc4.xml · nonDerivative · entry 1 Mirviss Jeffrey B. · CIK 0001566094 · SVP&Pres, Periph Intervent 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 93,286 Read SEC document |
| October 28, 2019 Filed Nov 12, 2019 21:04 UTC |
Butcher Arthur CSVP&Pres, Endoscopy
|
GiftCommon Stock | 2,497 | $0.00 | $0.00 |
DisclosureSEC source: 0001225208-19-014374 · doc4.xml · nonDerivative · entry 1 Butcher Arthur C · CIK 0001678249 · SVP&Pres, Endoscopy 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,919 F1 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 20:08 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 9,623 | $0.00 Strike: $13.08 | $0.00 |
DisclosureSEC source: 0001225208-19-013232 · doc4.xml · derivative · entry 3 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,253 Underlying: Common Stock · 9,623 shares Expires 2024-02-24 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F4 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 24, 2015, the first anniversary of the date of grant. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 20:08 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
SaleCommon Stock | 9,623 | $39.25 | $377,744.13 |
DisclosureSEC source: 0001225208-19-013232 · doc4.xml · nonDerivative · entry 2 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,194 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $38.98 to $39.44, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 03, 2019 Filed Oct 7, 2019 20:08 UTC |
Nanavaty MaulikSVP & Pres, Neuromodulation
|
Exercise / conversionCommon Stock | 9,623 | $13.08 | $125,868.84 |
DisclosureSEC source: 0001225208-19-013232 · doc4.xml · nonDerivative · entry 1 Nanavaty Maulik · CIK 0001529708 · SVP & Pres, Neuromodulation 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 264,817 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · balance_after: Includes shares acquired under the Boston Scientific Global Employee Stock Purchase Plan based upon the most current data available. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:13 UTC |
Brennan Daniel J.EVP and CFO
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 20,462 | $0.00 Strike: $7.41 | $0.00 |
DisclosureSEC source: 0001225208-19-013151 · doc4.xml · derivative · entry 3 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,463 Underlying: Common Stock · 20,462 shares Expires 2020-02-16 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F3 · derivative.exercise_date: Grant to the reporting person of an option to purchase a specified number of shares of common stock vesting in four equal annual installments beginning on February 16, 2011, the first anniversary of the date of grant. Read SEC document |
| October 02, 2019 Filed Oct 3, 2019 20:13 UTC |
Brennan Daniel J.EVP and CFO
|
SaleCommon Stock | 20,462 | $39.44 | $807,039.70 |
DisclosureSEC source: 0001225208-19-013151 · doc4.xml · nonDerivative · entry 2 Brennan Daniel J. · CIK 0001595612 · EVP and CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 214,960 F1 · kind: This transaction was effected pursuant to a pre-established Rule 10b5-1 trading plan. F2 · price: Represents the weighted average sale price. These shares were sold in multiple transactions at prices ranging from $39.05 to $39.85, inclusive. The reporting person undertakes to provide upon request by the U.S. Securities and Exchange Commission staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.